Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00268619 |
Study objectives:
Condition | Intervention | Phase |
---|---|---|
Myocardial Ischemia |
Drug: Ramipril |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Placebo-Controlled, Double-Blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes |
Study Start Date: | June 2004 |
Primary Completion Date: | July 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects presenting within 12 hours after the last episode of chest pain with:
Exclusion Criteria:
Responsible Party: | sanofi-aventis ( Medical Affairs Study Director ) |
Study ID Numbers: | HOE498/3501 |
Study First Received: | December 21, 2005 |
Last Updated: | July 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00268619 History of Changes |
Health Authority: | Canada: Health Canada |
Heart Diseases Myocardial Ischemia Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Cardiovascular Agents |
Ischemia Antihypertensive Agents Ramipril Insulin Protease Inhibitors |
Heart Diseases Molecular Mechanisms of Pharmacological Action Myocardial Ischemia Vascular Diseases Enzyme Inhibitors Cardiovascular Agents Ischemia Antihypertensive Agents |
Ramipril Pharmacologic Actions Protease Inhibitors Pathologic Processes Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases |